Navitoclax Most Promising BH3 Mimetic for Combination Therapy in Hodgkin Lymphoma

ABSTRACT: The treatment of young patients with Hodgkin lymphoma (HL) is often successful but a significant proportion of patients suffers from late toxicity. In the current era there are new opportunities for less toxic and more targeted treatment options. In this respect, the anti-apoptotic pathway is an attractive target since Hodgkin tumor cells abundantly express components of this pathway. We measured the effect of BH3 mimetics that interfere with anti-apoptotic proteins in cell lines, also in combination with the standard of care chemotherapeutic doxorubicin and the recently discovered preclinically active tamoxifen. Several anti-apoptotic BCL-2 family proteins were expressed in each case (n = 84) and in HL cell lines (n = 5). Cell lines were checked for sensitivity to BH3 mimetics by BH3 prof

SUBMITTER: Langendonk M 

PROVIDER: S-EPMC9699187 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature